Impact of RADA16 Use on Outcomes Following Tonsillectomy in Children
Start Date
7/9/2026
Completion Date
12/1/2027
Summary
The purpose of the research is to determine if RADA16 (also known as PuraStat®, PuraGel®, or PuraSinus®) improves patient outcomes following pediatric tonsillectomy procedures. Researchers will compare application of device RADA16 to application of no device to see if RADA16 works to treat post tonsillectomy hemorrhage.Participants will: Undergo tonsillectomy procedure. Receive and fill out a survey sent via email every 2 days following their procedure for 15 days, plus an additional survey on day 30, and track their symptoms.
Detailed Description
This is a prospective study evaluating the impact of intraoperative RADA16 application on the postoperative course following pediatric tonsillectomy as it relates to pain, bleeding, readmission, and use of a rescue analgesic (ex., oxycodone). We propose a randomized controlled trial whereby patients undergoing tonsillectomy would either receive a standard analgesic regimen (postoperative acetaminophen and NSAIDs plus oxycodone as a supplemental analgesic) versus intraoperative RADA16 application plus a standard analgesic regimen.
Eligibility Criteria
Age Range: 3 years to 17 years
Interventions
RADA16 hydrogel
Conditions
Locations
Cooperman Barnabas Medical Center
Livingston, New Jersey 07039
United States
University Hospital
Newark, New Jersey 07103
United States